Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Share-based Compensation (2016 - 2025)

Adma Biologics' Share-based Compensation history spans 13 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 0.75% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $20.0 million, up 47.08%, while the annual FY2025 figure was $20.0 million, 47.08% up from the prior year.
  • Share-based Compensation reached $5.4 million in Q4 2025 per ADMA's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q4 2024 to a low of $688274.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $2.4 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: plummeted 32.37% in 2023, then surged 211.35% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.2 million in 2021, then decreased by 11.88% to $1.1 million in 2022, then soared by 63.23% to $1.7 million in 2023, then soared by 211.35% to $5.4 million in 2024, then dropped by 0.75% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Share-based Compensation are $5.4 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025).